Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
Date:4/28/2008

NEW YORK, April 28 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on BioCurex Inc. (OTC Bulletin Board: BOCX). The full 52-page report can be found at http://www.crystalra.com.

BioCurex, Inc. ("BioCurex" or "the Company") is a biotechnology company developing products for cancer diagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by 2009. The Company uses a novel, patented technology based on the RECAF(TM) cancer marker, discovered by Dr. Ricardo Moro-Vidal, BioCurex's chief executive officer (CEO), president, and founder. RECAF(TM) is a molecule found on malignant cells but absent from most normal or benign cells. BioCurex believes that the detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and imaging techniques.

The RECAF(TM) marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF(TM) is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers. The Company's RECAF(TM) technology is reported to have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF(TM) recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate-specific antigen (PSA) test.

In early 2006, a RECAF(TM)-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex's aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF(TM) technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash thirty seven thousand five hundred dollars and one hundred and fifty thousand Options/Warrants to purchase BioCurex's stock for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
2. Measurement technique probes surface structure of gold nanocrystals
3. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
4. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
5. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
6. Alara Receives FDA Clearance to Market CRystalView T-Series CR system
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. New Independent Research Firm Targets Firms with Little or No Analyst Following
9. Inaugural Stanford International Pro-Am Winner A Remarkable Story in Determination And the Powerful Impact of St. Jude Childrens Research Hospital
10. Researchers important markers of high risk of type 2 diabetes
11. Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... MICHIGAN (PRWEB) , ... February 25, 2017 , ... The ... Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use of ... the human nervous system and how even small doses can be lethal. , Jay ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
Breaking Medicine Technology: